Infliximab improves skin involvement in psoriatic arthritis regardless of baseline psoriasis severity: Subanalysis of skin response from the IMPACT 2 trial - 21/08/11
Kim Papp, MD, PhD, Probity Medical Research, Waterloo, ON, Canada; Sunil Joshi, PhD, Cynthia Guzzo, MD, Centocor, Inc., Malvern, PA, United States; Gerald Krueger, MD, University of Utah Health Sciences Center, Salt Lake City, UT, United States
Le texte complet de cet article est disponible en PDF. P2768 Dr. Papp has received research grants from Centocor. Dr. Krueger is a consultant to Biogen, Genentech, and Centecor; on the sponsored speakers list for Amgen, Biogen, Genentech, and Centecor; and have participated in clinical trials for each of these companies. Neither Dr. Krueger nor his family owns stock in these companies. Studies have been funded by research grants from Centocor (IMPACT) or have been done by Centocor (IMPACT 2). |
Vol 52 - N° 3S
P. P188 - mars 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?